Health Care [ 10/12 ] | Pharmaceuticals [ 66/74 ]
NYSE | Common Stock
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
It operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products.
The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands.
It also offers contract manufacturing services.
The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies.
The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013.
Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 2, 24 | 0.53 Decreased by -15.87% | 0.46 Increased by +15.22% |
| May 7, 24 | 0.29 Decreased by -35.56% | 0.23 Increased by +26.09% |
| Feb 27, 24 | 0.86 Increased by +14.67% | 0.83 Increased by +3.61% |
| Nov 7, 23 | 0.64 Increased by +14.29% | 0.63 Increased by +1.59% |
| Aug 8, 23 | 0.63 Increased by +46.51% | 0.51 Increased by +23.53% |
| May 9, 23 | 0.45 Increased by +36.36% | 0.42 Increased by +7.14% |
| Feb 27, 23 | 0.75 Increased by +25.00% | 0.71 Increased by +5.63% |
| Nov 8, 22 | 0.56 Increased by +24.44% | 0.67 Decreased by -16.42% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 1.07 B Decreased by -10.68% | -105.70 M Decreased by -1.36 K% | Decreased by -9.92% Decreased by -1.51 K% |
| Mar 31, 24 | 1.08 B Decreased by -8.41% | 4.10 M Increased by +472.73% | Increased by +0.38% Increased by +506.96% |
| Dec 31, 23 | 1.16 B Increased by +0.14% | -32.30 M Decreased by -154.33% | Decreased by -2.79% Decreased by -153.98% |
| Sep 30, 23 | 1.12 B Increased by +2.15% | 14.20 M Increased by +127.26% | Increased by +1.26% Increased by +126.68% |
| Jun 30, 23 | 1.19 B Increased by +6.37% | 8.40 M Increased by +112.94% | Increased by +0.70% Increased by +112.17% |
| Mar 31, 23 | 1.18 B Increased by +9.98% | -1.10 M Increased by +15.38% | Decreased by -0.09% Increased by +23.06% |
| Dec 31, 22 | 1.16 B Increased by +4.56% | -12.70 M Decreased by -232.29% | Decreased by -1.10% Decreased by -226.52% |
| Sep 30, 22 | 1.10 B Increased by +5.51% | -52.10 M Increased by +11.54% | Decreased by -4.74% Increased by +16.17% |